|
"yang j c h"的相关文件
显示项目 396-428 / 428 (共9页)
<< < 1 2 3 4 5 6 7 8 9 > >>
每页显示[10|25|50]项目
| 國立成功大學 |
2017 |
Modulation of Biomarker Expression by Osimertinib: Results of the Paired Tumor Biopsy Cohorts of the AURA Phase I Trial
|
Thress, K.S.;Jacobs, V.;Angell, H.K.;Yang, J.C.-H.;Sequist, L.V.;Blackhall, F.;Su, W.-C.;Schuler, M.;Wolf, J.;Gold, K.A.;Cantarini, M.;Barrett, J.C.;J�nne, P.A. |
| 國立成功大學 |
2017 |
Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion study
|
Ahn, M.-J.;Kim, D.-W.;Cho, B.C.;Kim, S.-W.;Lee, J.S.;Ahn, J.-S.;Kim, T.M.;Lin, C.-C.;Kim, H.R.;John, T.;Kao, S.;Goldman, J.W.;Su, W.-C.;Natale, R.;Rabbie, S.;Harrop, B.;Overend, P.;Yang, Z.;Yang, J.C.-H. |
| 國立成功大學 |
2017 |
Genetic modifiers of progression-free survival in never-smoking lung adenocarcinoma patients treated with first-line tyrosine kinase inhibitors
|
Chang, I.-S.;Jiang, S.S.;Yang, J.C.-H.;Su, W.-C.;Chien, L.-H.;Hsiao, C.-F.;Lee, J.-H.;Chen, Chen C.-Y.;Chen, Chen C.-H.;Chang, G.-C.;Wang, Z.;Lo, F.-Y.;Chen, K.-Y.;Wang, Wang W.-C.;Chen, Y.-M.;Huang, M.-S.;Tsai, Y.-H.;Su, Y.-C.;Hsieh, W.-S.;Shih, W.-C.;Shieh, Shieh S.-H.;Yang, T.-Y.;Lan, Q.;Rothman, N.;Chen, Chen C.-J.;Chanock, S.J.;Yang, P.-C.;Hsiung, C.A. |
| 國立成功大學 |
2016-12 |
Phase I, dose-escalation study of the investigational drug D07001-F4, an oral formulation of gemcitabine HCl, in patients (pts) with advanced solid tumors or lymphoma
|
Lin, C. C.; Su, W. C.; Chao, Y.; Lee, J. H.; Hsu, C. H.; Cheng, A. L.; Chung, W. P.; Chen, M. H.; Lin, C. L.; Ho, H. L.; Huang, L. P.; Huang, C. T.; Hsueh, S. P.; Yang, J. C. H. |
| 國立臺灣大學 |
2016 |
Time to response in patients with ALK plus NSCLC receiving alectinib in the phase II NP28673 and NP28761 studies
|
Gandhi, L.; Gadgeel, S.; Shaw, A.; Barlesi, F.; Crino, L.; Yang, J. C-H.; Dingemans, A-M. C.; Kim, D-W.; de Marinis, F.; Schulz, M.; Liu, S.; Fish, S.; Kotb, A.; Ou, S-H. I.; 楊志新 |
| 國立臺灣大學 |
2016 |
Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial
|
Schuler, M.; Yang, J. C. -H.; Park, K.; Kim, J. -H.; Bennouna, J.; Chen, Y. -M.; Chouaid, C.; De Marinis, F.; Feng, J. -F.; Grossi, F.; Kim, D. -W.; Liu, X.; Lu, S.; Strausz, J.; Vinnyk, Y.; Wiewrodt, R.; Zhou, C.; Wang, B.; Chand, V. K.; Planchard, D.; 楊志新 |
| 臺大學術典藏 |
2016 |
Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial
|
Schuler, M.;Yang, J. C. -H.;Park, K.;Kim, J. -H.;Bennouna, J.;Chen, Y. -M.;Chouaid, C.;De Marinis, F.;Feng, J. -F.;Grossi, F.;Kim, D. -W.;Liu, X.;Lu, S.;Strausz, J.;Vinnyk, Y.;Wiewrodt, R.;Zhou, C.;Wang, B.;Chand, V. K.;Planchard, D.; 楊志新; Schuler, M.; Yang, J. C. -H.; Park, K.; Kim, J. -H.; Bennouna, J.; Chen, Y. -M.; Chouaid, C.; De Marinis, F.; Feng, J. -F.; Grossi, F.; Kim, D. -W.; Liu, X.; Lu, S.; Strausz, J.; Vinnyk, Y.; Wiewrodt, R.; Zhou, C.; Wang, B.; Chand, V. K.; Planchard, D. |
| 臺大學術典藏 |
2016 |
Efficacy of pemetrexed-based chemotherapy in patients with ROS1 fusion-positive lung adenocarcinoma compared with in patients harboring other driver mutations in East Asian populations
|
Chen Y.-F.; Hsieh M.-S.; Wu S.-G.; YIH-LEONG CHANG; Yu C.-J.; Yang J.C.-H.; Yang P.-C.; Shih J.-Y. |
| 臺大學術典藏 |
2016 |
Maximizing Benefits from Maintenance Pemetrexed with Stereotactic Ablative Radiotherapy in Oligoprogressive Non-Squamous Non-Small Cell Lung Cancer
|
Chen K.-Y.; Ho C.-C.; Yang J.C.-H.; CHIA-HSIEN CHENG; Hsu F.-M.; Lu S.-L.; Lu S.-L.;Hsu F.-M.;Chen K.-Y.;Ho C.-C.;Yang J.C.-H.;Chia-Hsien Cheng |
| 臺大學術典藏 |
2016 |
The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients
|
Yu C.-J.; Yang P.-C.; Yang J.C.-H.; Wen Y.-F.; JIN-YUAN SHIH; Chang Y.-L.; Tsai M.-F.; Wu S-G.;Liu Y.-N.;Tsai M.-F.;Chang Y.-L.;Yu C.-J.;Yang P.-C.;Yang J.C.-H.;Wen Y.-F.;Jin-Yuan Shih; Wu S-G.; Liu Y.-N. |
| 臺大學術典藏 |
2016 |
Anaplastic Lymphoma Kinase (ALK) Kinase Domain Mutation Following ALK Inhibitor(s) Failure in Advanced ALK Positive Non–Small-Cell Lung Cancer: Analysis and Literature Review
|
Lin Y.-T.; Yu C.-J.; Yang J.C.-H.; JIN-YUAN SHIH; Lin Y.-T.;Yu C.-J.;Yang J.C.-H.;Jin-Yuan Shih |
| 臺大學術典藏 |
2016 |
Coexistence of EGFR T790M mutation and common activating mutations in pretreatment non-small cell lung cancer: A systematic review and meta-analysis
|
Chen L.-Y.; Molina-Vila M.A.; Ruan S.-Y.; Su K.-Y.; Liao W.-Y.; KAI-LUN YU; Ho C.-C.; Shih J.-Y.; Yu C.-J.; Yang J.C.H.; Rosell R.; Yang P.-C. |
| 國立臺灣大學 |
2015 |
Efficacy by blind independent central review (BICR): Post hoc analyses of the phase III, multicentre, randomised IPASS study of 1st-line gefitinib (G) vs carboplatin/paclitaxel (C/P) in Asian patients (pts) with EGFR mutation-positive advanced NSCLC
|
Mok, T.; Saijo, N.; Thongprasert, S.; Yang, J. C. -H.; Wu, Y. -L.; Young, H.; Haddad, V.; Jiang, H.; Fukuoka, M.; 楊志新 |
| 國立臺灣大學 |
2015 |
Afatinib (A) versus chemotherapy (CT) for EGFR mutation-positive NSCLC patients (pts) aged >= 65 years: Subgroup analyses of LUX-Lung 3 (LL3) and LUX-Lung 6 (LL6)
|
Wu, Y. -L.; Sequist, L. V.; Geater, S. L.; Orlov, S.; Lee, K. H.; Tsai, C. -M.; Kato, T.; Kiura, K.; Barrios, C. H.; Schuler, M.; Hirsh, V.; Yamamoto, N.; O'Byrne, K.; Mok, T.; Massey, D.; Maerten, A.; Yang, J. C. -H.; 楊志新 |
| 國立臺灣大學 |
2015 |
EGFR Mutation Status Is Associated With Better Radiographic Response and Predicts Favorable Outcomes in Non-Small Cell Lung Cancer Patients With Brain Metastases Treated by Stereotactic Radiosurgery
|
Yang, W. C.; Xiao, F. R.; Shih, J. Y.; Ho, C. C.; Chen, Y. F.; Tseng, H. M.; Chen, K. Y.; Liao, W. Y.; Yu, C. J.; Yang, J. C. H.; Kuo, S. H.; Cheng, J. C. H.; Yang, P. C.; Hsu, F. M.; 曾漢民; 陳雅芳; 楊泮池; 廖唯昱; 郭頌鑫; 陳冠宇; 余忠仁; 成佳憲; 何肇基; 蕭輔仁; 施金元; 許?銘 |
| 臺大學術典藏 |
2015 |
The prognostic impact of type 2 diabetes mellitus on early cervical cancer in Asia
|
Kuo H.-Y.;Lin Z.-Z.;Kuo R.;Shau W.-Y.;Lai C.-L.;Yang Y.-Y.;Shao Y.-Y.;Hsu C.;Wen-Fang Cheng;Cheng A.-L.;Yang J.C.H.;Lai M.-S.; Kuo H.-Y.; Lin Z.-Z.; Kuo R.; Shau W.-Y.; Lai C.-L.; Yang Y.-Y.; Shao Y.-Y.; Hsu C.; WEN-FANG CHENG; Cheng A.-L.; Yang J.C.H.; Lai M.-S. |
| 臺大學術典藏 |
2015 |
Treating patients with ALK-positive non-small cell lung cancer: Latest evidence and management strategy
|
Yang J.C.H.; Shih J.Y; Chia-Chi Lin; Liao B.C |
| 臺大學術典藏 |
2015 |
Clinical and prognostic implications of RET rearrangements in metastatic lung adenocarcinoma patients with malignant pleural effusion
|
Tsai T.-H.; Wu S.-G.; Hsieh M.-S.; Yu C.-J.; Yang J.C.H.; JIN-YUAN SHIH |
| 臺大學術典藏 |
2015 |
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Non-Small-Cell Lung Cancer Patients with Leptomeningeal Carcinomatosis
|
YA-FANG CHEN; Chang C.-H.; Ho C.-C.; Shih J.-Y.; Yu C.-J.; Yang J.C.-H.; Lin C.-C.; Lee J.-H.; Liao B.-C. |
| 臺大學術典藏 |
2015 |
Advanced non-small cell lung cancer in the elderly: The impact of age and comorbidities on treatment modalities and patient prognosis
|
CHIA-LIN HSU; Chen J.-H.; Chen K.-Y.; Shih J.-Y.; Yang J.C.H.; Yu C.-J.; Yang P.-C. |
| 國立成功大學 |
2014-05-13 |
A phase I study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignancies
|
Lin, C-C; Su, W-C; Yen, C-J; Hsu, C-H; Su, W-P; Yeh, K-H; Lu, Y-S; Cheng, A-L; Huang, D. C-L; Fritsch, H.; Voss, F.; Taube, T.; Yang, J. C-H |
| 國立臺灣大學 |
2014 |
A phase I study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignancies
|
Lin, C-C; Su, W-C; Yen, C-J; Hsu, C-H; Su, W-P; Yeh, K-H; Lu, Y-S; Cheng, A-L; Huang, D. C-L; Fritsch, H.; Voss, F.; Taube, T.; Yang, J. C-H; 林家齊; 楊志新; 盧彥伸; 鄭安理; 徐志宏; 葉坤輝 |
| 臺大學術典藏 |
2014 |
Bcl-2-like protein 11 deletion polymorphism predicts survival in advanced non-small-cell lung cancer
|
Lee J.-H; Lin Y.-L; Hsu W.-H; Chen H.-Y; Chang Y.-C; Yu C.-J; Shih J.-Y; Chia-Chi Lin; Chen K.-Y; Ho C.-C; Laio W.-Y; Yang P.-C; Yang J.C.-H. |
| 臺大學術典藏 |
2014 |
Development of renal cysts after crizotinib treatment in advanced ALK-positive non-small-cell lung cancer
|
Yang P.-C.; JIN-YUAN SHIH; Wu S.-G.; Lin Y.-T.; Wang Y.-F.; Yang J.C.-H.; Yu C.-J. |
| 臺大學術典藏 |
2014 |
Bcl-2-like protein 11 deletion polymorphism predicts survival in advanced non-small-cell lung cancer
|
Lee J.-H.;Lin Y.-L.;Hsu W.-H.;Chen H.-Y.;Chang Y.-C.;Yu C.-J.;Shih J.-Y.;Lin C.-C.;Chen K.-Y.;Ho C.-C.;Laio W.-Y.;PAN-CHYR YANG;Yang J.C.-H.; Lee J.-H.; Lin Y.-L.; Hsu W.-H.; Chen H.-Y.; Chang Y.-C.; Yu C.-J.; Shih J.-Y.; Lin C.-C.; Chen K.-Y.; Ho C.-C.; Laio W.-Y.; PAN-CHYR YANG; Yang J.C.-H. |
| 臺大學術典藏 |
2014 |
Chlorhexidine for the prevention of bloodstream infection associated with totally implantable venous ports in patients with solid cancers
|
CHIUN HSU; Chang S.-Y.; Chien S.-F.; Chen Y.-C.; Hu F.-C.; Yang J.C.-H.; Cheng A.-L.; Yeh K.-H.; Chen I.-C.; Kao H.-F. |
| 臺大學術典藏 |
2013 |
Multi-gene analyses from waste brushing specimens for patients with peripheral lung cancer receiving EBUS-assisted bronchoscopy
|
Yu C.-J.; Yang J.C.H.; Yang P.-C.; Shih J.-Y.; Ruan S.-Y.; Tsai T.-H.;Ching-Yao Yang;Ho C.-C.;Liao W.-Y.;Jan I.-S.;Chen K.-Y.;Wang J.-Y.;Ruan S.-Y.;Yu C.-J.;Yang J.C.H.;Yang P.-C.;Shih J.-Y.; Tsai T.-H.; CHING-YAO YANG; Ho C.-C.; Liao W.-Y.; Jan I.-S.; Chen K.-Y.; Wang J.-Y. |
| 臺大學術典藏 |
2013 |
Multi-gene analyses from waste brushing specimens for patients with peripheral lung cancer receiving EBUS-assisted bronchoscopy
|
Tsai T.-H.; Yang C.-Y.; Ho C.-C.; Liao W.-Y.; Jan I.-S.; Chen K.-Y.; Wang J.-Y.; Ruan S.-Y.; Yu C.-J.; Yang J.C.H.; Yang P.-C.; JIN-YUAN SHIH |
| 臺大學術典藏 |
2013 |
ALDH-positive lung cancer stem cells confer resistance to epidermal growth factor receptor tyrosine kinase inhibitors
|
Huang C.-P.; Tsai M.-F.; Chang T.-H.; Tang W.-C.; Chen S.-Y.; Lai H.-H.; Lin T.-Y.; Yang J.C.H.; Yang P.-C.; JIN-YUAN SHIH; Lin S.-B. |
| 臺大學術典藏 |
2013 |
Phosphorylated insulin-like growth factor-1 receptor (pIGF1R) is a poor prognostic factor in brain metastases from lung adenocarcinomas
|
SHANG-GIN WU; Lin C.-H.; Cheng A.-L.; Lu Y.-S.; Shih J.-Y.; Yang J.C.-H.; Huang W.-C.; Wu P.-F. |
| 國立臺灣大學 |
2012 |
Nomogram to predict the presence of EGFR activating mutation in lung adenocarcinoma
|
Girard, N.; Sima, C. S.; Jackman, D. M.; Sequist, L. V.; Chen, H.; Yang, J. C-H.; Ji, H.; Waltman, B.; Rosell, R.; Taron, M.; Zakowski, M. F.; Ladanyi, M.; Riely, G.; Pao, W.; 楊志新 |
| 臺大學術典藏 |
2012 |
Genetic polymorphism of XRCC1 Arg399Gln is associated with survival in non-small-cell lung cancer patients treated with gemcitabine/platinum
|
WEI-YU LIAO; Shih J.-Y.; Chang G.-C.; Cheng Y.-K.; Yang J.C.-H.; Chen Y.-M.; Yu C.-J. |
| 臺大學術典藏 |
2012 |
Genetic polymorphism of XRCC1 Arg399Gln is associated with survival in non-small-cell lung cancer patients treated with gemcitabine/platinum
|
Liao W.-Y.; JIN-YUAN SHIH; Chang G.-C.; Cheng Y.-K.; Yang J.C.-H.; Chen Y.-M.; Yu C.-J. |
显示项目 396-428 / 428 (共9页)
<< < 1 2 3 4 5 6 7 8 9 > >>
每页显示[10|25|50]项目
|
